Prostatype Genomics AB (publ) (FRA:PGO0)

Market Cap	2.52M -34.3%
Revenue (ttm)	54.89K -69.0%
Net Income	-4.11M
EPS	-0.12
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0214
Previous Close	0.0308
Day's Range	0.0214 - 0.0318
52-Week Range	0.0138 - 0.1410
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 20, 2026

About Prostatype Genomics AB

Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests. The company offers a Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, RTqPCR kit, patient database and algorithms, Prostatype Web System (PWS), and tumor stage, as well as calculates the P-score. Its test is based on a database containing prostate cancer patients; and provides decision support for patients and doctors when making a treatment decision. The company was incorporated in 200...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2007
• Employees: 7
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: PGO0

Financial Performance

In 2025, Prostatype Genomics AB's revenue was 594,000, a decrease of -69.03% compared to the previous year's 1.92 million. Losses were -44.50 million, 8.41% more than in 2024.

Financial numbers in SEK

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jun 26, 2026

Data Sources Report a data error